A Difficile Challenge: The Impact of New Therapies on
Clinical Outcomes and Economics in C. Difficile Infection

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live webinars held on March 20, 2018 and April 10, 2018. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from May 20, 2018 to May 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck & Co

Clostridium difficile, a Gram-positive bacteria that causes diarrhea, abdominal bloating, and colitis, is associated with significant morbidity and mortality. Up to 25% of patients with an initial episode of C. difficile infection (CDI) experience disease recurrence. Recurrent CDI is particularly challenging to manage. Although a number of therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. This webinar will provide attendees with up-to-date knowledge of evidence-based treatment and management strategies of initial and recurrent CDI to improve clinical and economic outcomes.

Upon Completion of this activity, participants will be able to:

  • Analyze the recently updated IDSA and SHEA clinical practice guidelines for the management of CDI

  • Discuss how changes to the clinical practice guidelines will change management in CDI

  • Examine therapeutic agents and regimens that reduce the occurrence of antimicrobial resistance and improve outcomes for patients with CDI

  • Analyze the clinical efficacy and safety of biologics for prevention of recurrent CDI

  • Identify patients at risk for CDI based on history, presentation, and the appropriate risk stratification techniques

Faculty: Ciarán P. Kelly, MD
Professor of Medicine
Harvard Medical School
Director, Gastroenterology Fellowship Training
Medical Director, Celiac Center
Beth Israel Deaconess Medical Center


Dr. Kelly serves as a consultant and/or on an advisory board for Biocodex, Merck, Seres Therapeutics, Summit, and Synthetic Biologies. He received grant/research support from the Institut Merieux, Merck, and the National Institutes of Health. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Co

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue